Business Description
Rallybio is a clinical-stage company focused on developing treatments for patients with serious and uncommon medical conditions. Its most advanced drug candidate, RLYB116, targets a specific part of the immune system and has already completed an early-stage human trial, while a second candidate, RLYB332, is being developed to address severe anemia caused by the body's inability to produce healthy red blood cells. The company works alongside AbCellera and Johnson & Johnson to broaden its research efforts, including developing solutions for pregnant women whose unborn children face certain blood-related risks. Founded in 2018 and based in New Haven, Connecticut, Rallybio aims to bring meaningful relief to people living with conditions that currently have few or no treatment options.
